These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 17558485

  • 1. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.
    Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR.
    Diabetologia; 2007 Aug; 50(8):1752-62. PubMed ID: 17558485
    [Abstract] [Full Text] [Related]

  • 2. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
    McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR.
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1746-55. PubMed ID: 17848629
    [Abstract] [Full Text] [Related]

  • 3. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.
    Irwin N, McClean PL, O'Harte FP, Gault VA, Harriott P, Flatt PR.
    Diabetologia; 2007 Jul; 50(7):1532-40. PubMed ID: 17486314
    [Abstract] [Full Text] [Related]

  • 4. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.
    Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O'harte FP, Flatt PR.
    Diabetes; 2005 Aug; 54(8):2436-46. PubMed ID: 16046312
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.
    Irwin N, McClean PL, Hunter K, Flatt PR.
    Diabetes Obes Metab; 2009 Jun; 11(6):603-10. PubMed ID: 19515180
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC, Lavery KS, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Gault VA, Flatt PR.
    J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP.
    McClean PL, Gault VA, Irwin N, McCluskey JT, Flatt PR.
    Diabetes Obes Metab; 2008 Apr; 10(4):336-42. PubMed ID: 18333892
    [Abstract] [Full Text] [Related]

  • 14. Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice.
    Pathak V, Gault VA, Flatt PR, Irwin N.
    Mol Cell Endocrinol; 2015 Feb 05; 401():120-9. PubMed ID: 25449420
    [Abstract] [Full Text] [Related]

  • 15. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
    McShane LM, Irwin N, O'Flynn D, Franklin ZJ, Hewage CM, O'Harte FP.
    J Endocrinol; 2016 Jun 05; 229(3):319-30. PubMed ID: 27098830
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
    Irwin N, Montgomery IA, Moffett RC, Flatt PR.
    Biochem Pharmacol; 2013 Jan 01; 85(1):81-91. PubMed ID: 23085436
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of diets rich in sucrose, coconut fat and safflowerseed oil on the development of the obese hyperglycaemic (ob/ob) syndrome in mice.
    Flatt PR, Bailey CJ, Kwasowski P, Swanston-Flatt SK.
    Diabetes Res; 1990 Jan 01; 13(1):23-8. PubMed ID: 2097092
    [Abstract] [Full Text] [Related]

  • 20. Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes?
    Flatt PR.
    Diabet Med; 2008 Jul 01; 25(7):759-64. PubMed ID: 18513308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.